Business News: Zydus Cadila and TLC from Taiwan make pact to market anti-black fungus drug in India.
Zydus Cadila and Taiwan-based specialty pharmaceutical company TLC on Wednesday said they entered into a pact to market liposomal amphotericin B, a crucial drug for treating mucormycosis (black mold), in India.
The companies announced that they have signed an agreement to market AmphoTLC (Amphotericin B Liposome for Injection 50mg) in India, Zydus Cadila said in a statement.
“With India facing a severe shortage of the drug to treat mucormycosis, we are making this key drug available in India on an immediate basis,” said Cadila Healthcare MD Sharvil Patel. he needs the moment to address this life-threatening infection with safe and effective therapy, he added.
The Central Drugs Standard Control Organization has approved TLC’s new drug application (NDA) for Amphotericin B Liposome for Injection 50 mg for immediate import according to the approved use and indication, Zydus Cadila said.
With cases of black fungi on the rise in India in recent days, AmphoTLC will address the country’s acute liposomal amphotericin B deficiency, he added. Mucormycosis is a severe fungal infection, also known as a black fungus, and COVID-19-associated mucormycosis is life-threatening, the statement said.
AmphoTLC is a liposomal amphotericin B injection indicated for severe systemic fungal infections such as mucormycosis, he added. Shares of Cadila Healthcare, the listed entity of the Zydus Group, were trading at Rs 626.45 per scrip on BSE, up 0.64% from the previous closure. PTI AKT